Markets

For Antares Pharma, Inc. (ATRS), It May Be As Good A Moment

Antares Pharma, Inc. (NASDAQ:ATRS) seems to be forming a pattern of major movements, providing only some crumbs of outlook for market participants trying to figure out its next move. Now trading with a market value of 458.54M, the company has a mix of catalysts and obstacles that spring from the nature of its operations. Everyone seems to have their own opinion of this stock. But what do the numbers really say? We think it’s a great time to take a fresh look.

Antares Pharma, Inc. (NASDAQ:ATRS) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For ATRS, the company currently has 23.11 million of cash on the books. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has 71.44 million in total assets, balanced by 43.19 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

Antares Pharma, Inc. (ATRS) saw -6.09 million in free cash flow last quarter, representing a quarterly net change in cash of -3.45 million. Perhaps most importantly where cash movements are concerned, the company saw about -6.03 million in net operating cash flow.

Antares Pharma, Inc. (NASDAQ:ATRS) Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 12.7 million in total revenues. That represents a quarterly year/year change in revenues of 0.06 in sequential terms, the ATRS saw sales decline by -0.10.



But what about the bottom line? After all, that’s what really matters in the end. Antares Pharma, Inc. (ATRS) is intriguing when broken down to its core data. The cost of selling goods last quarter was 7.19 million, yielding a gross basic income of 5.52 million. For shareholders, given the total diluted outstanding shares of 156.72 million, this means overall earnings per share of -0.04. Note, this compares with a consensus analyst forecast of -0.01 in earnings per share for its next fiscal quarterly report.

Is Antares Pharma, Inc. (NASDAQ:ATRS) Valuation Attractive

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about 0.06 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 67.50. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Antares Pharma, Inc..

Previous ArticleNext Article

Related Post

Looking at the Big Picture for Leucadia National C... Leucadia National Corporation (NYSE:LUK) seems to be forming a pattern of major movements, providing only some crumbs of outlook for market participan...
It’s worth it to have a look at Axovant Scie... Axovant Sciences Ltd. (NASDAQ:AXON) trade is getting exciting but lets take a deeper look whether it is as good a moment. Now trading with a market va...
The Bank of New York Mellon Corporation (BK) Raisi... The Bank of New York Mellon Corporation (NYSE:BK) is one of the active stocks and its unusual movement is raising eyebrows among traders. Now trading ...
How Insiders and Institutions are Trading Facebook... Recent insider trends for Facebook, Inc. (NASDAQ:FB) have caught the attention of investors. Analysts monitor insider data to understand the sentiment...
The Long Case For Marathon Oil (MRO) Marathon Oil Corporation (NYSE:MRO) is on our radar right now but there could still be some opportunities on the horizon. Now trading with a market va...